Individual case safety reports how to determine the onset date of an adverse reaction: A survey

Drug Safety

Volumn 34, Issue 4, 2011, Pages 299-305

  Klepper, Michael J ^a,c   Edwards, Brian ^b  

^a Michael J Klepper MD   (United States)

^b Pharmacovigilance and Drug Safety   (United Kingdom)

^c 102 Lulworth Court ^*  (United States)

Author keywords

Adverse drug reactions; Adverse reaction monitoring; Legislation; Pharmacovigilance; Postmarketing surveillance; Questionnaires.

Indexed keywords

HERBACEOUS AGENT;

ADVERSE DRUG REACTION; ARTICLE; CASE REPORT; DRUG SURVEILLANCE PROGRAM; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; INDIVIDUAL CASE SAFETY REPORT; MEDICAL DOCUMENTATION; MEDICAL STAFF; NARRATIVE; PHYSICAL DISEASE BY BODY FUNCTION; PNEUMONIA; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DRUG TOXICITY; HUMANS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PILOT PROJECTS; QUESTIONNAIRES;

EID: 79952773341     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11588490-000000000-00000     Document Type: Article

References (14)

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting E2A. Geneva: ICH Secretariat, 2004, Oct [online]. Available from URL:http:// www.ich.org/products/guidelines/ efficacy/article/efficacyguidelines.html [Accessed 2011 Jan 21].
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Post-approval safety data management: definitions and standards for expedited reporting E2D. Geneva: ICH Secretariat 2003 Nov [online]. Available from URL: http://www.ich.org/products/ guidelines/efficacy/ article/efficacy-guidelines.html [Accessed 2011 Jan 21].
3. CIOMS V. Current challenges in pharmacovigilance: pragmatic approaches. Geneva: Council for International Organizations of Medical Sciences, 2001.
4. US Department of Health and Human Services, Food and Drug Administration. Form voluntary reporting (form FDA 3500) [online]. Available from URL: http://www.fda. gov/Safety/MedWatch/HowToReport/DownloadForms/de fault.htm [Accessed 2011 Jan 21].
5. US Department of Health and Human Services, Food and Drug Administration. Form mandatory reporting (form FDA 3500A) [online]. Available from URL: http://www. fda.gov/Safety/MedWatch/HowToReport/DownloadForms/ default.htm [Accessed 2011 Jan 21].
6. Council for International Organizations ofMedical Sciences [online]. Available from URL: http://www.cioms.ch/form/ frame-form.htm [Accessed 2011 Jan 21].
7. US Department of Health and Human Services, Food and Drug Administration. Vaccine Adverse Event Reporting System (VAERS) [online]. Available from URL: https:// vaers.hhs.gov/esub/index [Accessed 2011 Jan 21].
8. Public Health Agency of Canada. Adverse events following immunization reporting form [online]. Available from URL: http://www.phac-aspc.gc.ca/im/aefi- form-eng.php [Accessed 2011 Jan 21].
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Revision of the ICH guideline on clinical safety data management data element for transmission of individual safety reports E2B (R2). Geneva: ICH Secretariat, 2005 May [online]. Available from URL: http:// www.ich.org/products/guidelines/efficacy/article/ efficacyguidelines.html [Accessed 2011 Jan 21].
10. Center for Drug Evaluation and Research, Food and Drug Administration. The clinical impact of adverse event reporting [online]. Available from URL:http://www.fda. gov/downloads/Safety/MedWatch/UCM168505.pdf [Accessed 2011 Jan 21].
11. KellyWN, Barnes J, BergmanU, et al.Guidelines for submitting adverse reports for publication. Drug Saf 2007; 30: 367-73. (Pubitemid 46740334)
12. US FDA. Patient profile viewer: notice of pilot project [online]. Available from URL: http://www.federalregister. gov/articles/2001/12/10/01- 30430/patient-profile-viewer-no tice-of-pilot-project [Accessed 2011 Jan 21].
13. Edwards B, Prabhakar U. Postmarketing safety surveillance: issues with data collection for postmarketing pharmacovigilance. Pharm Med 2010; 24 (6): 1-6.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical development Q8 (R2). Geneva: ICH Secretariat 2009 Aug [online]. Available from URL: http://www.ich.org/products/guidelines/quality/article/ quality-guidelines.html [Accessed 2011 Jan 21]